SCHEMBL1496789

SCHEMBL1496789

Cc1cccc(OCC(O)CO)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.71
MAPK1 P28482 1/20 0.71
ADRB2 P07550 3/20 0.66
ADRB1 P08588 3/20 0.66
KMT2A Q03164 5/20 0.58
MEN1 O00255 4/20 0.58
L3MBTL1 Q9Y468 1/20 0.57
MAPT P10636 2/20 0.54
HIF1A Q16665 1/20 0.53
HTT P42858 1/20 0.52
KDM4E B2RXH2 1/20 0.51
CYP1A2 P05177 1/20 0.51
GAA P10253 2/20 0.50
HTR1A P08908 1/20 0.50
ADRA2C P18825 1/20 0.50
SLC6A4 P31645 1/20 0.50
ADRA1A P35348 1/20 0.50
HTR2B P41595 1/20 0.50
SLC6A3 Q01959 1/20 0.50
KCNH2 Q12809 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14896741 1.00 TSHR (0.71) TSHRMAPK1ADRB2ADRB1KMT2A
SCHEMBL16002431 1.00 TSHR (0.71) TSHRMAPK1ADRB2ADRB1KMT2A
SCHEMBL29366942 1.00 TSHR (0.71) TSHRMAPK1ADRB2ADRB1KMT2A
SCHEMBL10922740 0.91 ADRB2 (0.71) TSHRMAPK1ADRB2ADRB1KMT2A
SCHEMBL18654313 0.90 TSHR (0.58) TSHRMAPK1ADRB2ADRB1KMT2A
SCHEMBL3671328 0.87 MAPK1 (0.83) TSHRMAPK1ADRB2ADRB1KMT2A
SCHEMBL14173781 0.87 TSHR (0.58) TSHRMAPK1ADRB2ADRB1KMT2A
SCHEMBL1496742 0.86 ADRB2 (0.66) TSHRMAPK1ADRB2ADRB1KMT2A
SCHEMBL1496524 0.85 ADRB2 (0.64) TSHRMAPK1ADRB2ADRB1KMT2A
SCHEMBL1496641 0.85 ADRB2 (0.64) TSHRMAPK1ADRB2ADRB1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112996489-A Sol-gel composition 株式会社爱茉莉太平洋 2021-06-18 CN claimed
US-20260103839-A1 Method For Producing Transfer Medium And Transfer Recording Method SEIKO EPSON CORP (JP) 2026-04-16 US disclosed
EP-4112695-B1 TREATMENT LIQUID COMPOSITION, SET OF INK JET INK COMPOSITION AND TREATMENT LIQUID COMPOSITION, AND TREATMENT METHOD SEIKO EPSON CORP (JP) 2026-01-21 EP disclosed
US-20250361676-A1 INKJET TEXTILE PRINTING METHOD SAKATA INX CORP (JP) 2025-11-27 US disclosed
US-20250303772-A1 Method For Producing Transfer Medium SEIKO EPSON CORPORATION (JP) 2025-10-02 US disclosed
US-20250304814-A1 Treatment Liquid And Recording Method SEIKO EPSON CORPORATION (JP) 2025-10-02 US disclosed
EP-4585658-A1 INKJET-TEXTILE PRINTING METHOD Sakata INX Corporation (JP) 2025-07-16 EP disclosed
US-12305052-B2 Ink set, recording method, and recording device SEIKO EPSON CORPORATION (JP) 2025-05-20 US disclosed
US-20250128533-A1 Transfer Recording Method SEIKO EPSON CORPORATION (JP) 2025-04-24 US disclosed
US-20250059391-A1 Recording Method And Ink Set SEIKO EPSON CORPORATION (JP) 2025-02-20 US disclosed
WO-2010003048-A1 BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2010-01-07 WO disclosed
WO-2009146358-A1 IMIDAZOPYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2009-12-03 WO disclosed
WO-2009134973-A1 QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2009-11-05 WO disclosed
EP-1380342-B1 COMPLEX CATALYST, PROCESS FOR PRODUCING THE COMPLEX CATALYST, AND PROCESS FOR PRODUCING ALCOHOL DERIVATIVE WITH THE COMPLEX CATALYST SUMITOMO CHEMICAL CO (JP) 2009-07-01 EP disclosed
US-20090012330-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-01-08 US disclosed
EP-1982972-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-10-22 EP disclosed
EP-1982973-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-10-22 EP disclosed
US-6995110-B2 Complex catalyst, process for producing the complex catalyst, and process for producing alcohol derivative with the complex catalyst SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-02-07 US disclosed
US-20040077487-A1 Complex catalyst, process for producing the complex catalyst, and process for producing alchohol derivative with the complex catalyst SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2004-04-22 US disclosed
EP-1380342-A1 COMPLEX CATALYST, PROCESS FOR PRODUCING THE COMPLEX CATALYST, AND PROCESS FOR PRODUCING ALCOHOL DERIVATIVE WITH THE COMPLEX CATALYST SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2004-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012330-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND ADH1A, ADH1C, ADH5 TSHR 1213/4885MAPK1 1367/4885ADRB2 1220/4885
US-20260103839-A1 Method For Producing Transfer Medium And Transfer Recording Method ICAM1, TRRAP, ACTN4 TSHR 4014/4885MAPK1 172/4885ADRB2 1734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.